Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9738504 | 0.88 | GPR119 (0.44) | ALDH1A1GPR119KDM4EMEN1MAPT | |
| SCHEMBL9250150 | 0.86 | KDM4E (0.46) | ALDH1A1GPR119KDM4E | |
| SCHEMBL8870492 | 0.86 | KDM4E (0.46) | ALDH1A1GPR119KDM4E | |
| SCHEMBL3826056 | 0.86 | KDM4E (0.46) | ALDH1A1GPR119KDM4E | |
| SCHEMBL3827938 | 0.86 | KDM4E (0.46) | ALDH1A1GPR119KDM4E | |
| SCHEMBL9645053 | 0.85 | GPR119 (0.42) | ALDH1A1GPR119KDM4EMEN1MAPT | |
| SCHEMBL9717959 | 0.85 | GPR119 (0.42) | ALDH1A1GPR119KDM4EMEN1MAPT | |
| SCHEMBL9264341 | 0.85 | GPR119 (0.42) | ALDH1A1GPR119KDM4EMEN1MAPT | |
| SCHEMBL9263028 | 0.85 | ALDH1A1 (0.42) | ALDH1A1GPR119KDM4EMEN1MAPT | |
| SCHEMBL9717989 | 0.84 | GPR119 (0.41) | ALDH1A1GPR119KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992019618-A1 | PLATELET ACTIVATING ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-11-12 | — | — | WO | disclosed |